BFRG
Bullfrog AI Holdings, Inc. Common Stock·Healthcare
0.89
14.837%(−0.15)
Market ClosedLast Updated: — ET
52W L: $0.4252W H: $2.12
BFRG NEWS
defenseworld.net
Apr 2
Bullfrog AI Holdings Inc. (NASDAQ:BFRG) Short Interest Down 15.0% in March
Bullfrog AI Holdings Inc. (NASDAQ: BFRG - Get Free Report) was the recipient of a large decline in short interest in March. As of March 13th, there was short interest totaling 550,568 shares, a decline of 15.0% from the February 26th total of 647,761 shares. Based on an average daily volume of 146,928 shares, the days-to-cover
benzinga.com
Mar 31
BullFrog AI Shares Surge On Deal With Top Pharma Company For MDD Drug Targets
BullFrog said the agreement will utilize its end-to-end analytical AI platform to accelerate the partner's drug discovery and clinical development program for MDD.
invezz.com
Mar 30
Bullfrog AI stock offers a rare opportunity for investors to take profit
Bullfrog AI Inc more than doubled on Mar. 30 after announcing a landmark commercial agreement with a “top 5” pharma leader to identify novel therapeutic targets for Major Depressive Disorder. In its press release, BFRG said the pharmaceutical giant has agreed to use its proprietary bfLEAP® platform – providing high-profile validation of its machine-leaning-driven drug discovery tech.
benzinga.com
Mar 30
Dow Gains 200 Points; Bullfrog AI Shares Jump
U.S. stocks traded mostly higher this morning, with the Dow Jones index gaining around 200 points on Monday.
globenewswire.com
Mar 30
BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder
GAITHERSBURG, Md., March 30, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, today announced a commercial agreement with a top 5 global pharmaceutical company in 2025 by revenue (“Customer”), to apply the Company's proprietary bfLEAP® platform to identify and prioritize novel drug targets in major depressive disorder (MDD), accelerating the Customer's drug discovery and clinical development program for this indication. The agreement also provides exclusive access to a target candidate. The MDD market was valued at more than $8 billion in 2025 and expected to grow at an average annual rate of nearly 5% to reach in excess of $11 billion by 2032, according to Stellar Market Research.
globenewswire.com
Mar 25
BullFrog AI Unveils bfARENAS™ Scenario-based Decision Engine
Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial strategies to build diversified, risk-balanced R&D portfolios Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial strategies to build diversified, risk-balanced R&D portfolios
